GlobeNewswire

WSO2 Delivers Platform-Wide Support for GDPR with New Product Developments

Dela
WSO2 cloud-native, open source platform empowers enterprises to rapidly comply with EU data privacy requirements and create new GDPR-driven digital business offerings

MOUNTAIN VIEW, Calif., April 05, 2018 (GLOBE NEWSWIRE) -- Time is running out to comply with the General Data Protection Regulation (GDPR) that goes into effect May 2018. Mandated by the European Parliament and European Union (EU) Council, the regulation is aimed at harmonizing data privacy laws across Europe to protect all data belonging to citizens and residents. As a result, it affects any enterprise that conducts business in or with EU markets. Significantly, in addressing GDPR's requirements, organizations have an opportunity to set the stage for new digital business models that drive revenues and growth. To support these enterprises, WSO2 today announced its Spring 2018 Release update, featuring product developments designed to offer platform-wide support for GDPR.

WSO2's Spring 2018 Release includes new features and updates across all products, solutions, and services, which together empower organizations to rapidly comply with GDPR. Among these are additions to WSO2's identity access management (IAM), API management, enterprise integration, and analytics offerings designed to ensure the security and privacy of personal data throughout the processes of collection, processing, storage, and destruction.

By delivering its functionality on a cloud-native, open source platform, WSO2 facilitates the agility and innovation required to thrive in rapidly evolving markets driven by disruptive technologies and digital business models. Now with WSO2's platform-wide support for GDPR, enterprises can accelerate their digital transformation efforts by capitalizing on data, insights and services generated through compliance with the regulation.

"In today's global economy, avoiding the GDPR data privacy mandate isn't an option. It will impact every organization worldwide that wants to engage with European residents online," said WSO2 CEO Tyler Jewell. "With our Spring 2018 Release, we are delivering the integrated products and services that will empower enterprises to comply with GDPR in as little as 60 days while laying the groundwork to deliver new digital products based on secure GDPR-compliant data."

In addition to the new product capabilities, WSO2 is offering a series of seven webinars to help organizations accelerate their GDPR compliance. To learn more about the GDPR implementation best practices covered in the webinars, as well as how to participate, visit https://wso2.com/solutions/regulatory-compliance/gdpr/#Events.

Facilitating GDPR Compliance
WSO2's Spring 2018 Release offers several technology developments designed not only to help organizations meet the regulatory requirements of GDPR, but also enhance their long-term growth potential through new services and greater efficiency.

Consent management and privacy toolkit in  WSO2 Identity Server enable enterprise data controllers to accelerate their organization's GDPR compliance. In addition to the new consent management functionality and the privacy toolkit, the Spring 2018 Release of WSO2 Identity Server also introduces personal information export capabilities and support for encrypting OpenID Connect identity tokens. Together, these new features address the different aspects of individual rights defined in GDPR, such as the "right to be forgotten" and the "right to personal data portability" among others, in order to ensure the protection of personal information.

Collaborative API and application lifecycle management with  WSO2 API Manager allows APIs and applications to be shared within and across organizations. The Spring 2018 product version also features the ability to anonymize user identities, in line with GDPR requirements to provide users with the right to be forgotten. If a user requests that personal data be removed from the system, organizations can anonymize that specific user's unique universal identification from multiple locations.

The API and application lifecycle management capabilities also can be deployed via a GDPR-compliant hybrid cloud solution that provides organizations a local gateway rather than a cloud API gateway. This lets users take advantage of the cloud's scalability and agility while ensuring that all API calls occur locally, thus increasing security and minimizing latency. Moreover, it is easy to maintain, since users simply supply their cloud credentials, and the gateway pulls the configuration and changes from the cloud.

Open source and GDPR-ready integration capabilities with  WSO2 Enterprise Integrator enable connections and data transformations across legacy systems, SaaS applications, services, and APIs. The Spring 2018 Release incorporates significant enhancements to scripting, caching, and analytics functionality that allow organizations to efficiently automate task execution and store data in a GDPR-compliant manner and gain insights into performance.

Streaming analytics capabilities with  WSO2 Stream Processor (formerly named WSO2 Data Analytics Server) empower organizations to derive meaningful insights with available data. The Spring 2018 version of the product includes functionality to support GDPR compliance, such as the ability to anonymize both login user information and any data stored in databases.

WSO2 Open Banking  for financial firms,  which launched in August 2017, complements today's new product releases by providing the functionality to comply with both GDPR and the European Union's second Payment Services Directive (PSD2). Security features that support full GDPR compliance include user consent, user profile management, and cookie handling, among others.

Enhanced Subscription Benefits
WSO2's Spring 2018 Release product developments are complemented by enhancements to WSO2 Subscription, WSO2's commercial offering, which features access to WSO2 Update for continuous delivery of bug fixes, security updates, and performance enhancements, along with WSO2 Support for 24x7 support. Among the enhanced WSO2 Subscription benefits are the increase of support lifetime for WSO2 product versions to 10 years; new installation options, including Docker images, Docker Compose, and Vagrant; and a new release of WSO2 Update Manager. In addition to the included solutions and services, WSO2 Subscription offers options for training, consulting, and WSO2 Managed Cloud services.

Enterprises also can take advantage of a free 15-day trial of WSO2 Subscription to assist users evaluating WSO2 products and services. A Free Trial Subscription provides access to an account management and solution architecture team, along with access to all Subscription benefits, including five hours of query support.

About WSO2
WSO2 is the #1 open source integration vendor. It offers a complete platform that enables businesses to integrate, manage, govern and process any application, data or system-on-premises or in the cloud. Enterprises and governments across the world rely on WSO2's consulting and subscriptions that accelerate the evolution of any digital native initiative. Today, over 450 enterprise customers representing the world's best brands, process more than 5 trillion transactions through WSO2 each year. Visit https://wso2.com to learn more.

Trademarks and registered trademarks are the properties of their respective owners.

PR Contact
Shifali Erasmus
Kinetic.PR, LLC for WSO2
shifali@kineticprllc.com
Mobile: 650-544-6424




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: WSO2, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum